v3.26.1
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)
12 Months Ended
Aug. 07, 2025
Nov. 12, 2024
Nov. 11, 2024
Nov. 08, 2024
May 13, 2024
Feb. 23, 2023
Mar. 15, 2022
Mar. 11, 2022
Oct. 12, 2021
Mar. 31, 2026
Mar. 31, 2025
Oct. 31, 2025
Dec. 31, 2024
Jun. 01, 2023
Cash consideration for shares                   $ 4,353,842        
Reverse stock split       1-for-10 reverse stock split                    
Common stock, par value       $ 0.001           $ 0.001 $ 0.001      
Preferred stock, par value       $ 0.001                    
Share based compensation arrangement by share based payment award options grants in period gross, shares                   100,000        
Share Price                   $ 1.90        
Novi Thera [Member]                            
Acquired percentage                       50.10%    
Orocidin A/S [Member]                            
Acquired percentage         95.00%               100.00%  
Bio-Convert A/S [Member]                            
Acquired percentage                         100.00%  
Alteral Therapeutics [Member]                            
Equity method investment ownership percentage                       49.90%    
Orocidin A/S [Member] | Restricted Stock [Member]                            
Number of shares issued   200,000                        
Common Stock [Member]                            
Number of shares issued                   1,850,036        
Cash consideration for shares                   $ 1,850        
Number of shares issued for acquisition                     12,000,000      
Mag Mile Capital Inc [Member]                            
Ownership percentage acquired                           4.99%
Orocidin A/S [Member]                            
Ownership percentage acquired   5.00% 5.34%   95.00%                  
Number of shares issued for acquisition     200,000   3,800,000                  
Bio-Convert A/S [Member]                            
Ownership percentage acquired     100.00%                      
Number of shares issued for acquisition     12,000,000                      
Stock Purchase Agreement [Member]                            
Reverse stock split       1-for-10 reverse stock split                    
Contribution Agreement [Member]                            
Number of shares issued           250,000                
Outstanding shares percentage           100.00%                
Directors Agreement [Member] | Mr. Ritter [Member]                            
Annual cash retainer amount $ 10,000                          
Share based compensation arrangement by share based payment award options grants in period gross, shares 50,000                          
Share Price $ 1.90                          
Directors Agreement [Member] | Messrs. Jensen [Member]                            
Share based compensation arrangement by share based payment award options grants in period gross, shares 25,000                          
Share Price $ 1.90                          
Reddington Partners LLC [Member] | Stock Purchase Agreement [Member]                            
Number of shares issued                 511,448          
Outstanding shares percentage             90.00%   90.00%          
Cash consideration for shares                 $ 400,000          
Reverse stock split               1-for-50 reverse stock split            
Common stock owned             511,448              
Reddington Partners LLC [Member] | Stock Purchase Agreement [Member] | First Closing [Member]                            
Number of shares issued               42,273            
Reddington Partners LLC [Member] | Stock Purchase Agreement [Member] | Second Closing [Member]                            
Number of shares issued             469,175              
Orocidin A/S [Member] | Common Stock [Member]                            
Outstanding shares percentage   5.00%                        
Number of shares issued   29,663